Raras
Buscar doenças, sintomas, genes...
Variante de xeroderma pigmentoso
ORPHA:90342CID-10 · Q82.1CID-11 · LD27.YOMIM 278750DOENÇA RARA

A variante de Xeroderma Pigmentoso é um tipo mais leve de Xeroderma Pigmentoso (XP), uma doença genética de pele rara marcada por uma sensibilidade extrema ao sol e um risco maior de desenvolver câncer de pele.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A variante de Xeroderma Pigmentoso é um tipo mais leve de Xeroderma Pigmentoso (XP), uma doença genética de pele rara marcada por uma sensibilidade extrema ao sol e um risco maior de desenvolver câncer de pele.

Publicações científicas
223 artigos
Último publicado: 2025 Nov

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
50
pacientes catalogados
Início
Adolescent
+ adult
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q82.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧬
Pele e cabelo
6 sintomas
👁️
Olhos
2 sintomas
📏
Crescimento
1 sintomas
🧠
Neurológico
1 sintomas

+ 12 sintomas em outras categorias

Características mais comuns

100%prev.
Fotossensibilidade cutânea
Muito frequente (99-80%)
100%prev.
Sardas em áreas expostas ao sol
Muito frequente (99-80%)
100%prev.
Telangiectasia cutânea
Obrigatório (100%)
100%prev.
Início na infância
Obrigatório (100%)
90%prev.
Hipopigmentação da pele
Muito frequente (99-80%)
90%prev.
Hiperpigmentação da pele
Muito frequente (99-80%)
22sintomas
Muito frequente (7)
Frequente (7)
Ocasional (1)
Muito raro (3)
Sem dados (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 22 características clínicas mais associadas, ordenadas por frequência.

Fotossensibilidade cutâneaCutaneous photosensitivity
Muito frequente (99-80%)100%
Sardas em áreas expostas ao solFreckles in sun-exposed areas
Muito frequente (99-80%)100%
Telangiectasia cutâneaCutaneous telangiectasia
Obrigatório (100%)100%
Início na infânciaInfantile onset
Obrigatório (100%)100%
Hipopigmentação da peleHypopigmentation of the skin
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico223PubMed
Últimos 10 anos44publicações
Pico20188 papers
Linha do tempo
2025Hoje · 2026📈 2018Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

POLHDNA polymerase etaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

DNA polymerase specifically involved in the DNA repair by translesion synthesis (TLS) (PubMed:10385124, PubMed:11743006, PubMed:16357261, PubMed:20388628, PubMed:24449906, PubMed:24553286, PubMed:38212351). Due to low processivity on both damaged and normal DNA, cooperates with the heterotetrameric (REV3L, REV7, POLD2 and POLD3) POLZ complex for complete bypass of DNA lesions. Inserts one or 2 nucleotide(s) opposite the lesion, the primer is further extended by the tetrameric POLZ complex. In th

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
HDR through Homologous Recombination (HRR)Translesion Synthesis by POLHTermination of translesion DNA synthesis
MECANISMO DE DOENÇA

Xeroderma pigmentosum variant type

An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. XPV shows normal nucleotide excision repair, but an exaggerated delay in recovery of replicative DNA synthesis. Most patients with the variant type of xeroderma pigmentosum do not develop clinical symptoms and skin neoplasias until a later age. Clinical manifestations are limited to photo-induced deterioration of the skin and eyes.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
39.4 TPM
Fibroblastos
31.8 TPM
Testículo
21.5 TPM
Cervix Ectocervix
11.3 TPM
Tireoide
11.2 TPM
OUTRAS DOENÇAS (1)
xeroderma pigmentosum variant type
HGNC:9181UniProt:Q9Y253

Variantes genéticas (ClinVar)

111 variantes patogênicas registradas no ClinVar.

🧬 POLH: NM_006502.3(POLH):c.127A>T (p.Lys43Ter) ()
🧬 POLH: NM_006502.3(POLH):c.1202del (p.Thr401fs) ()
🧬 POLH: NM_006502.3(POLH):c.660+4A>T ()
🧬 POLH: NM_006502.3(POLH):c.43G>C (p.Asp15His) ()
🧬 POLH: NM_006502.3(POLH):c.1244+207T>A ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 246 variantes classificadas pelo ClinVar.

185
49
12
Patogênica (75.2%)
VUS (19.9%)
Benigna (4.9%)
VARIANTES MAIS SIGNIFICATIVAS
POLH: NM_006502.3(POLH):c.505C>T (p.Gln169Ter) [Pathogenic]
POLH: NM_006502.3(POLH):c.2130dup (p.Leu711fs) [Likely pathogenic]
POLH: NM_006502.3(POLH):c.1727_1728del (p.Pro576fs) [Likely pathogenic]
POLH: NM_006502.3(POLH):c.788G>T (p.Gly263Val) [Likely pathogenic]
POLH: NM_006502.3(POLH):c.533_534del (p.Leu178fs) [Likely pathogenic]

Vias biológicas (Reactome)

3 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Variante de xeroderma pigmentoso

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
43 papers (10 anos)
#1

Uncovering the Role of DNA Repair Impairment in UVA-Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells.

Molecular carcinogenesis2025 Nov

Ultraviolet A (UVA) radiation induces DNA damage both directly, by forming cyclobutane pyrimidine dimers (CPDs), and indirectly, by generating oxidative stress. Cells rely on nucleotide excision repair (NER) and translesion synthesis (TLS) to tolerate these lesions. Xeroderma pigmentosum variant (XP-V) cells, deficient in DNA polymerase eta (pol eta), exhibit a heightened risk of skin cancer due to impaired TLS. While XP-V patients are considered NER-proficient, our findings challenge this assumption by demonstrating that UVA-induced oxidative stress impaired NER activity, leading to increased C > T transitions at CPD sites. Whole-exome sequencing of UVA-irradiated XP-V cells revealed a substantial rise in mutations, with a distinct C > T signature characteristic of defective CPD repair. Notably, pretreatment with the antioxidant N-acetylcysteine (NAC) mitigated this effect, reducing C > T transitions through enhanced NER function and decreasing C > A transversions via its antioxidant properties. These results redefine the mutagenic landscape of XP-V cells, revealing that oxidatively generated damage to NER proteins-rather than TLS deficiency alone-contributes to their elevated mutation burden. Our findings suggest that antioxidant strategies may partially protect XP-V patients from UVA-driven mutagenesis enhancing the cells' DNA repair capacity, ultimately reducing skin cancer and contributing to better overall health outcomes.

#2

Four germline POLH variants, including two found in skin tumors, impair DNA polymerase η function and cellular tolerance to UV radiation and cisplatin.

Chemico-biological interactions2025 Aug 01

DNA polymerase (pol) η is vital for accurately replicating DNA opposite ultraviolet light (UV)-induced cyclobutane pyrimidine dimers and cisplatin-induced intrastrand purine crosslinks. While human POLH deficiency is linked to the disease xeroderma pigmentosum variant, the functional consequences of germline and somatic POLH variants remain largely unexplored. We characterized nine nonsynonymous POLH germline variants, five of which have also been found in various tumors. Enzyme activity was first assessed using recombinant pol η (residues 1-432) proteins. Variants F17S, C227Y, and R356X displayed substantially reduced or nearly abolished polymerase activity opposite cis-syn cyclobutane thymine dimer (CTD) compared to the wild-type. Cellular effects were then evaluated in POLH-deficient human embryonic kidney (HEK) 293 cells. Unlike cells transfected with wild-type POLH, cells transfected with F17S, R81C, C227Y, or R356X variants failed to rescue UV- and cisplatin-sensitivity. Interestingly, the R81C variant protein was undetectable in transfected cells. Further steady-state kinetic analysis revealed that the F17S, C227Y, and R356X variants had 3- to 5000-fold reductions in kcat/Km values for correct dATP insertion opposite CTD, while the R81C variant exhibited kinetics comparable to the wild-type enzyme. CRISPR/Cas9-mediated knock-in of the R81C variant in HEK 293T cells was associated with significantly impaired pol η protein expression and increased cisplatin sensitivity. Notably, R81C and R356X mutations have been reported in skin cancer samples. These findings suggest that R81C, F17S, C227Y, and R356X POLH variants-underexpressed or hypoactive-may be insufficient to protect cells from UV radiation and cisplatin, highlighting their potential implications for individual susceptibility to UV and cisplatin damage.

#3

Evaluation of Photoaging and Sun Protection Behavior in Children With Xeroderma Pigmentosum, Group C: A Prospective Analysis.

Pediatric dermatology2025

Thirteen children with xeroderma pigmentosum variant C were evaluated using the Dermoscopic Photoaging Assessment Scale (DPAS), the Glogau scale, and the Sun Protection Behavior Scale (SPBS). Most patients exhibited signs of epidermal photoaging, with pigmentary and vascular changes and poor sun protection behavior (mean SPBS score: 18.92 ± 5.69). The mean DPAS score of 13.15 correlated with the Glogau scale and ocular severity score. Sun protection behavior improved significantly at 6 months after repeated reinforcement of sun protection measures (35 ± 5.68).

#4

A Case of Xeroderma Pigmentosum Variant Type With a Novel Mutation Diagnosed in Early Childhood.

Photodermatology, photoimmunology &amp; photomedicine2025 Jan
#5

Canonical and Non-Canonical Roles of Human DNA Polymerase η.

Genes2024 Sep 27

DNA damage tolerance pathways that allow for the completion of replication following fork arrest are critical in maintaining genome stability during cell division. The main DNA damage tolerance pathways include strand switching, replication fork reversal and translesion synthesis (TLS). The TLS pathway is mediated by specialised DNA polymerases that can accommodate altered DNA structures during DNA synthesis, and are important in allowing replication to proceed after fork arrest, preventing fork collapse that can generate more deleterious double-strand breaks in the genome. TLS may occur directly at the fork, or at gaps remaining behind the fork, in the process of post-replication repair. Inactivating mutations in the human POLH gene encoding the Y-family DNA polymerase Pol η causes the skin cancer-prone genetic disease xeroderma pigmentosum variant (XPV). Pol η also contributes to chemoresistance during cancer treatment by bypassing DNA lesions induced by anti-cancer drugs including cisplatin. We review the current understanding of the canonical role of Pol η in translesion synthesis following replication arrest, as well as a number of emerging non-canonical roles of the protein in other aspects of DNA metabolism.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC108 artigos no totalmostrando 43

2025

Uncovering the Role of DNA Repair Impairment in UVA-Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells.

Molecular carcinogenesis
2025

Four germline POLH variants, including two found in skin tumors, impair DNA polymerase η function and cellular tolerance to UV radiation and cisplatin.

Chemico-biological interactions
2025

Evaluation of Photoaging and Sun Protection Behavior in Children With Xeroderma Pigmentosum, Group C: A Prospective Analysis.

Pediatric dermatology
2025

A Case of Xeroderma Pigmentosum Variant Type With a Novel Mutation Diagnosed in Early Childhood.

Photodermatology, photoimmunology &amp; photomedicine
2024

Canonical and Non-Canonical Roles of Human DNA Polymerase η.

Genes
2024

Cutaneous Squamous Cell Carcinoma and Multiple Basal Cell Carcinomas in Xeroderma Pigmentosum-Variant Type Treated with Imiquimod 5% Cream and Radiotherapy: A Case Report.

Acta medica Philippina
2024

Homozygous substitution of threonine 191 by proline in polymerase η causes Xeroderma pigmentosum variant.

Scientific reports
2024

The accurate bypass of pyrimidine dimers by DNA polymerase eta contributes to ultraviolet-induced mutagenesis.

Mutation research
2023

Mutational signatures and increased retrotransposon insertions in xeroderma pigmentosum variant skin tumors.

Carcinogenesis
2023

Identification of Three Human POLH Germline Variants Defective in Complementing the UV- and Cisplatin-Sensitivity of POLH-Deficient Cells.

International journal of molecular sciences
2023

Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy.

NAR cancer
2023

Nontraditional Roles of DNA Polymerase Eta Support Genome Duplication and Stability.

Genes
2023

A compound heterozygous Chinese patient with xeroderma pigmentosum variant type caused by novel POLH variants.

Experimental dermatology
2022

Changes in the architecture and abundance of replication intermediates delineate the chronology of DNA damage tolerance pathways at UV-stalled replication forks in human cells.

Nucleic acids research
2022

A new POLH mutation in a consanguineous Chinese family with xeroderma pigmentosum variant type.

Clinical and experimental dermatology
2022

Current state of knowledge of human DNA polymerase eta protein structure and disease-causing mutations.

Mutation research. Reviews in mutation research
2022

Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.

Acta oncologica (Stockholm, Sweden)
2022

DNA polymerase eta protects human cells against DNA damage induced by the tumor chemotherapeutic temozolomide.

Mutation research. Genetic toxicology and environmental mutagenesis
2021

Novel pathogenic frameshift mutation in the POLH gene contributes to xeroderma pigmentosum variant type in a 16-year-old girl.

The Australasian journal of dermatology
2021

Xeroderma pigmentosum variant: squamous cell carcinoma of the lower lip harboring exon 11 mutation of POLH.

Oral surgery, oral medicine, oral pathology and oral radiology
2020

Angiosarcoma of the Auricle in a Patient with Xeroderma Pigmentosum Variant.

Case reports in dermatology
2020

Novel variants in POLH and TREM2 genes associated with a complex phenotype of xeroderma pigmentosum variant type and early-onset dementia.

Molecular genetics &amp; genomic medicine
2020

Rare exon 10 deletion in POLH gene in a family with xeroderma pigmentosum variant correlating with protein expression by immunohistochemistry.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
2020

Lentigo maligna in a patient with xeroderma pigmentosum, variant type: A case report with dermoscopic findings and review of the literature.

Photodermatology, photoimmunology &amp; photomedicine
2020

The Iberian legacy into a young genetic xeroderma pigmentosum cluster in central Brazil.

Mutation research. Genetic toxicology and environmental mutagenesis
2020

Large deletions in immunoglobulin genes are associated with a sustained absence of DNA Polymerase η.

Scientific reports
2020

Whole-exome sequencing reveals the impact of UVA light mutagenesis in xeroderma pigmentosum variant human cells.

Nucleic acids research
2019

Exome-based search for recurrent disease-causing alleles in Russian population.

European journal of medical genetics
2019

The key role of UVA-light induced oxidative stress in human Xeroderma Pigmentosum Variant cells.

Free radical biology &amp; medicine
2018

Variant subtype of xeroderma pigmentosum diagnosed in a 77-year-old woman.

JAAD case reports
2018

Filling gaps in translesion DNA synthesis in human cells.

Mutation research. Genetic toxicology and environmental mutagenesis
2019

ATR/Chk1 Pathway is Activated by Oxidative Stress in Response to UVA Light in Human Xeroderma Pigmentosum Variant Cells.

Photochemistry and photobiology
2018

Whole genome sequencing and 6-year follow-up of a mother and daughter with frontometaphyseal dysplasia associated with keratitis, xerosis, poikiloderma, and acro-osteolysis: A case report.

Medicine
2018

Differential Roles of Rad18 and Chk2 in Genome Maintenance and Skin Carcinogenesis Following UV Exposure.

The Journal of investigative dermatology
2018

Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis.

Cell cycle (Georgetown, Tex.)
2018

Angiosarcoma arising on the scalp in a Korean patient with xeroderma pigmentosum variant type.

Photodermatology, photoimmunology &amp; photomedicine
2018

Xeroderma Pigmentosum Diagnosis Using a Flow Cytometry-Based Nucleotide Excision Repair Assay.

The Journal of investigative dermatology
2017

Diagnosis of Xeroderma pigmentosum variant in a young patient with two novel mutations in the POLH gene.

American journal of medical genetics. Part A
2017

Molecular diagnosis of xeroderma pigmentosum variant in an isolated population: the interface between precision medicine and public health.

The British journal of dermatology
2016

O6-2'-Deoxyguanosine-butylene-O6-2'-deoxyguanosine DNA Interstrand Cross-Links Are Replication-Blocking and Mutagenic DNA Lesions.

Chemical research in toxicology
2015

129-Derived Mouse Strains Express an Unstable but Catalytically Active DNA Polymerase Iota Variant.

Molecular and cellular biology
2015

Aberrant C-terminal domain of polymerase η targets the functional enzyme to the proteosomal degradation pathway.

DNA repair
2015

UV-induced mutations in epidermal cells of mice defective in DNA polymerase η and/or ι.

DNA repair
Ver todos os 108 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Variante de xeroderma pigmentoso.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Variante de xeroderma pigmentoso

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Uncovering the Role of DNA Repair Impairment in UVA-Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells.
    Molecular carcinogenesis· 2025· PMID 40794023mais citado
  2. Four germline POLH variants, including two found in skin tumors, impair DNA polymerase &#x3b7; function and cellular tolerance to UV radiation and cisplatin.
    Chemico-biological interactions· 2025· PMID 40334807mais citado
  3. Evaluation of Photoaging and Sun Protection Behavior in Children With Xeroderma Pigmentosum, Group C: A Prospective Analysis.
    Pediatric dermatology· 2025· PMID 39731425mais citado
  4. A Case of Xeroderma Pigmentosum Variant Type With a Novel Mutation Diagnosed in Early Childhood.
    Photodermatology, photoimmunology &amp; photomedicine· 2025· PMID 39673222mais citado
  5. Canonical and Non-Canonical Roles of Human DNA Polymerase &#x3b7;.
    Genes· 2024· PMID 39457395mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:90342(Orphanet)
  2. OMIM OMIM:278750(OMIM)
  3. MONDO:0010214(MONDO)
  4. GARD:5630(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q32143762(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Variante de xeroderma pigmentoso
Compêndio · Raras BR

Variante de xeroderma pigmentoso

ORPHA:90342 · MONDO:0010214
Prevalência
<1 / 1 000 000
Casos
50 casos conhecidos
Herança
Autosomal recessive
CID-10
Q82.1 · Xeroderma pigmentoso
CID-11
Início
Adolescent, Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0432328
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades